PL EN


Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników
Czasopismo
2013 | 8 | 6 | 830-834
Tytuł artykułu

sRAGE is associated with low waist circumference and Hb levels in NAFLD

Treść / Zawartość
Warianty tytułu
Języki publikacji
EN
Abstrakty
EN
Advanced glycation end products (AGEs) and the receptor RAGE interaction is involved in nonalcoholic fatty liver disease (NAFLD). Although exogenously administered soluble RAGE (sRAGE) has been shown to block the harmful effects of AGEs in animal models, there is still controversy about the role of sRAGE in humans. We examined here which anthropometric, metabolic and clinical variables were independent correlates of sRAGE levels in NAFLD patients. The study involved 77 biopsy-proven, unmedictaed NAFLD patients (44 male and 33 female) with a mean age of 43.4±13.0 years old. We examined which anthropometric, metabolic and clinical variables, including liver steatosis and fibrosis markers, are independently associated with serum levels of sRAGE. Mean serum levels of sRAGE were 710.7±290.2 pg/mL. Univariate analysis revealed that waist circumference (inversely), hemoglobin (inversely), number of white blood cells (inversely), total-bilirubin (inversely), free fatty acid (inversely), ferritin (inversely), and HbA1c (inversely) were significantly correlated with serum levels of sRAGE. In multiple stepwise regression analysis, waist circumference (p<0.01, inversely) and hemoglobin (p<0.01, inversely) were independently associated with serum levels of sRAGE (R2=0.176). The present study reveals that low serum levels of sRAGE are independently associated with waist circumference and hemoglobin in patients with NAFLD.
Słowa kluczowe
EN
Wydawca

Czasopismo
Rocznik
Tom
8
Numer
6
Strony
830-834
Opis fizyczny
Daty
wydano
2013-12-01
online
2013-12-06
Twórcy
  • Department of Medicine and Molecular Sciences, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, 734-8553, Japan
  • Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume University School of Medicine, Kurume, 830-0011, Japan, shoichi@med.kurume-u.ac.jp
autor
  • Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume University School of Medicine, Kurume, 830-0011, Japan
  • Department of Medicine and Molecular Sciences, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, 734-8553, Japan
autor
  • Department of Medicine and Molecular Sciences, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, 734-8553, Japan
  • Department of Medicine and Molecular Sciences, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, 734-8553, Japan
Bibliografia
  • [1] Yamagishi S, Imaizumi T: Diabetic vascular complications: Pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 2005; 11: 2279–2299 http://dx.doi.org/10.2174/1381612054367300[Crossref]
  • [2] Hyogo H, Yamagishi S: Advanced glycation end products (AGEs) and their involvement in liver disease. Curr Pharm Des 2008; 14: 969–972 http://dx.doi.org/10.2174/138161208784139701[Crossref][WoS]
  • [3] Kimura Y, Hyogo H, Yamagishi S, et al: Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH. J Gastroenterol 2010; 45: 750–757 http://dx.doi.org/10.1007/s00535-010-0203-y[WoS][Crossref]
  • [4] Iwamoto K, Kanno K, Hyogo H, et al: Advanced glycation end products enhance the proliferation and activation of hepatic stellate cells. J Gastroenterol 2008; 43: 298–230 http://dx.doi.org/10.1007/s00535-007-2152-7[WoS][Crossref]
  • [5] Yamagishi S, Matsui T: Soluble form of a receptor for advanced glycation end products (sRAGE) as a biomarker. Front Biosci (Elite Ed) 20101; 2: 1184–1195
  • [6] Yamagishi S, Adachi H, Nakamura K, et al: Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects. Metabolism 2006; 55: 1227–1231 http://dx.doi.org/10.1016/j.metabol.2006.05.007[Crossref]
  • [7] Yilmaz Y, Ulukaya E, Gul OO, Arabul M et al: Decreased plasma levels of soluble receptor for advanced glycation endproducts (sRAGE) in patients with nonalcoholic fatty liver disease. Clin Biochem 2009; 42: 802–807 http://dx.doi.org/10.1016/j.clinbiochem.2009.02.003[WoS][Crossref]
  • [8] Nakamura K, Adachi H, Matsui T, et al: Independent determinants of soluble form of receptor for advanced glycation end products in elderly hypertensive patients. Metabolism 2009; 58: 421–425 http://dx.doi.org/10.1016/j.metabol.2008.10.020[Crossref][WoS]
  • [9] Unoki H, Bujo H, Yamagishi S, et al: Advanced glycation end products attenuate cellular insulin sensitivity by increasing the generation of intracellular reactive oxygen species in adipocytes. Diabetes Res Clin Pract 2006; 76: 236–244 http://dx.doi.org/10.1016/j.diabres.2006.09.016[WoS][Crossref]
  • [10] Semba RD, Ferrucci L, Sun K, et al: Elevated serum advanced glycation end products and their circulating receptors are associated with anaemia in older community-dwelling women. Age Ageing 2009; 38: 283–289 http://dx.doi.org/10.1093/ageing/afp011[Crossref][WoS]
  • [11] Iwata H, Ukeda H, Maruyama T, et al: Effect of carbonyl compounds on red blood cells deformability. Biochem Biophys Res Commun 2004; 321: 700–706 http://dx.doi.org/10.1016/j.bbrc.2004.07.026[Crossref]
  • [12] Wautier JL, Wautier MP, Schmidt AM, et al: Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications. Proc Natl Acad Sci USA 1994; 91: 7742–7746 http://dx.doi.org/10.1073/pnas.91.16.7742[Crossref]
Typ dokumentu
Bibliografia
Identyfikatory
Identyfikator YADDA
bwmeta1.element.-psjd-doi-10_2478_s11536-013-0224-z
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.